What we’ve achieved
HPP worked with an International Expert Advisory Group to develop the Radioligand Therapy Readiness Assessment Framework, which is the first tool of its kind. As this highly targeted and safe cancer treatment is being sought out by patients and clinicians alike, barriers to its implementation must be addressed to enable equitable access.
The framework has been made available in the public domain under a Creative Commons licence, to enable stakeholders anywhere in the world to apply it to their own national context. It is accompanied by a user guide, explaining each step of the assessment in turn and containing methodology used to create the framework.
The framework was launched on 9 June 2021 at an ancillary event to the American Society of Clinical Oncology Conference.
HPP has also worked with experts to apply the framework to the UK and US health systems. The adapted framework for the UK was launched at a webinar on 9 September 2021, along with a situation analysis and policy blueprint based on the findings from the UK assessment. The adapted framework for the US and its associated materials were launched at a webinar on 3 November 2021.
In 2022, we launched the Radioligand Therapy Readiness Hub, which collects examples highlighting different ways of improving the integration of radioligand therapy into cancer care, and boosting readiness for the approach in the future. This was followed in 2023 by the launch of the Radiopharmaceuticals Patient Advocacy Toolkit, an online resource for patient advocates to learn more about the use of radiopharmaceutical diagnostics and treatments, and how to advocate for equitable access to them.
Building on our experience of creating frameworks, in 2023 we developed a report in partnership with the European Health Management Association: Health system readiness for innovation: putting research into practice to drive effective implementation . The report outlines the principles required for the effective implementation of innovations and highlights how frameworks can be used to help achieve this.
This is part of a longer-term project on radioligand therapy that HPP has led since 2019.
